Rituxan 500 MG/50 ML vial 50ML
Ended Awarded
- Contract number
- SPE2DR26FMDT3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $30,443
Award facts
- Contract value 100% obligated
- $30,442.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $30,442.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 500 mg/50 mL vials of Rituxan, a monoclonal antibody immunosuppressant used in treating various cancers and autoimmune conditions. The delivery order, issued without set-aside designation, is scheduled for completion by November 18, 2025, and represents one of numerous recent awards to the contractor through the Defense Logistics Agency's Medical Supply Chain division. DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical distribution network, with no identified subcontractors on this award.
This delivery order falls under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying IDC, valued at $499,999,999 through December 31, 2036, authorizes the contractor to supply a comprehensive range of pharmaceuticals, biologics, and medical consumables to support Department of Defense healthcare operations globally. The company's selection as a regional prime vendor contractor reflects its demonstrated capability to fulfill the diverse and specialized pharmaceutical requirements of military medical facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FMDT3?
SPE2DR26FMDT3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DR26FMDT3 worth?
The government has obligated $30,443 on SPE2DR26FMDT3.
Is contract SPE2DR26FMDT3 an order under another contract?
Yes. SPE2DR26FMDT3 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDT3 competed?
The extent of competition for SPE2DR26FMDT3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award